[ad_1]
travellinglight/iStock by way of Getty Images
Shortly after a U.Ok. watchdog declined to endorse Biogen’s (NASDAQ:BIIB) Alzheimer’s drug Leqembi to be used within the nation’s nationwide well being service (NHS), The Telegraph reported Saturday that their Eli Lilly (NYSE:LLY) will face the identical destiny for its drug, donanemab.
The National Institute for Health and Care Excellence (NICE), which units drug coverage for the NHS, issued draft steering on Friday, noting that using Leqembi within the NHS wouldn’t be a cheap means of spending taxpayer cash.
Its rebuke got here shortly after the U.Ok. drug regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), accredited the anti-amyloid infusion, making Great Britain the primary European nation to approve the remedy.
However, citing well being sources, the newspaper mentioned that the NHS would “positively” reject LLY’s drug, donanemab.
Based on the drug’s facet impact profile, the paper added that the MHRA could not even approve donanemab, which requires a month-to-month administration as opposed to Leqembi’s biweekly routine.
“Now that Nice has rejected lecanemab, it positively is not going to approve donanemab, which additionally has twice the chance of significant negative effects,” a supply mentioned.
Branded within the U.S. as Kisunla, donanemab has an identical mechanism however is probably going to be much more costly with an annual price ticket of £25K, 25% increased than Leqembi’s.
Eli Lilly (LLY) and Biogen’s accomplice for Leqembi Eisai (OTCPK:ESALF) (OTCPK:ESAIY) have but to reply to feedback. MHRA and NICE declined to touch upon ongoing opinions.
More on Biogen, Eisai, and so forth.
[ad_2]
Source: Seekingalpha